Page 59 - Read Online

Page 12 of 12 Armstrong et al. Hepatoma Res 2021;7:18 I http://dx.doi.org/10.20517/2394-5079.2020.118

64. FDA. FDA approves atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma. Available from: https://www.fda.gov/
drugs/drug-approvals-and-databases/fda-approves-atezolizumab-plus-bevacizumab-unresectable-hepatocellular-carcinoma 2020;Content
current as of: 06/01/2020. [Last accessed on 16 Dec 2020]
65. FDA. FDA grants accelerated approval to nivolumab and ipilimumab combination for hepatocellular carcinoma Available from: https://
www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-nivolumab-and-ipilimumab-combination-
hepatocellular-carcinoma 2020;Content current as of: 03/11/2020. [Last accessed on 16 Dec 2020]
66. Lang L. FDA approves sorafenib for patients with inoperable liver cancer. Gastroenterology 2008;134:379.
67. Sasaki A, Kai S, Iwashita Y, Hirano S, Ohta M, Kitano S. Microsatellite distribution and indication for locoregional therapy in small
hepatocellular carcinoma. Cancer 2005;103:299-306.
68. Shi M, Zhang CQ, Zhang YQ, Liang XM, Li JQ. Micrometastases of solitary hepatocellular carcinoma and appropriate resection margin.
World J Surg 2004;28:376-81.
69. Suh SW, Choi YS. Predictors of Micrometastases in Patients with Barcelona Clinic Liver Cancer Classification B Hepatocellular
Carcinoma. Yonsei Med J 2017;58:737-42.
70. Ali MY, Grimm CF, Ritter M, et al. Activation of dendritic cells by local ablation of hepatocellular carcinoma. J Hepatol 2005;43:817-22.
71. Dromi SA, Walsh MP, Herby S, et al. Radiofrequency ablation induces antigen-presenting cell infiltration and amplification of weak
tumor-induced immunity. Radiology 2009;251:58-66.
72. Dagoglu N, Karaman S, Caglar HB, Oral EN. Abscopal Effect of Radiotherapy in the Immunotherapy Era: Systematic Review of
Reported Cases. Cureus 2019;11:e4103.
73. Liu Y, Dong Y, Kong L, Shi F, Zhu H, Yu J. Abscopal effect of radiotherapy combined with immune checkpoint inhibitors. J Hematol
Oncol 2018;11:104.
74. Aerts M, Benteyn D, Van Vlierberghe H, Thielemans K, Reynaert H. Current status and perspectives of immune-based therapies for
hepatocellular carcinoma. World J Gastroenterol 2016;22:253-61.
75. Tai WMD, Loke KSH, Gogna A, et al. A phase II open-label, single-center, nonrandomized trial of Y90-radioembolization in combination
with nivolumab in Asian patients with advanced hepatocellular carcinoma: CA 209-678. J Clin Oncol 2020;38:4590-4590.
76. Kaseb AO, Cao HST, Mohamed YI, et al. Final results of a randomized, open label, perioperative phase II study evaluating nivolumab
alone or nivolumab plus ipilimumab in patients with resectable HCC. J Clin Oncol 2020;38:4599-4599.
77. Flecken T, Schmidt N, Hild S, et al. Immunodominance and functional alterations of tumor-associated antigen-specific CD8 + T-cell
responses in hepatocellular carcinoma. Hepatology 2014;59:1415-26.
78. Gao Q, Qiu SJ, Fan J, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular
carcinoma after resection. J Clin Oncol 2007;25:2586-93.
79. Liang J, Ding T, Guo ZW, et al. Expression pattern of tumour-associated antigens in hepatocellular carcinoma: association with immune
infiltration and disease progression. Br J Cancer 2013;109:1031-9.
80. Unitt E, Marshall A, Gelson W, et al. Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver
transplantation. J Hepatol 2006;45:246-53.
81. Hsu CH, Lu S, Abbas A, et al. Longitudinal and personalized detection of circulating tumor DNA (ctDNA) for monitoring efficacy of
atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma (HCC). J Clin Oncol 2020;38:3531-3531.
82. Zhu AX, Guan Y, Abbas AR, et al. Abstract CT044: Genomic correlates of clinical benefits from atezolizumab combined with
bevacizumab vs. atezolizumab alone in patients with advanced hepatocellular carcinoma (HCC). Cancer Research 2020;80:CT044-
CT044.
83. Alexandrov LB, Nik-Zainal S, Wedge DC, et al; Australian Pancreatic Cancer Genome Initiative., ICGC Breast Cancer Consortium.,
ICGC MMML-Seq Consortium., ICGC PedBrain. Signatures of mutational processes in human cancer. Nature 2013;500:415-21.
84. Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature
2013;499:214-8.
85. Shrestha R, Prithviraj P, Anaka M, et al. Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular
Carcinoma. Front Oncol 2018;8:269.